| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 22, 2012Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
-
Feb 21, 2012Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company...
-
Feb 17, 2012Distinguished by Superior Deliverability and Diabetes Indication, New Heart Device Becomes Available to Cath Labs Nationwide
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 17, 2012-- Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (